COVID-19 updates, including vaccine information, for our patients and visitors Learn More

Menu
Search

UCSD Research Reveals Mechanism Involved With Type of Fatal Epilepsy

 

September 19, 2005  |  

Researchers at University of California, San Diego (UCSD) have found that Lafora disease, an inherited form of epilepsy that results in death by the age of 30, can be caused by mutations in a gene that regulates the concentration of the protein laforin. These findings are reported in the current issue of Proceedings of the National Academy of Sciences (PNAS).

Lafora disease is characterized by normal development for the first decade of life, followed by an initial seizure in the second decade, progressively worsening seizures, early dementia, and death within 10 years of onset. Medications can ease the severity of initial symptoms, but there is no long-term treatment or cure for the disease.

A puzzling aspect of the disease is the accumulation of starch-/glycogen-like granules in most tissues of Lafora disease patients. Thus, researchers have long thought that a defect in glycogen metabolism is intimately linked to the disease. Recessive mutations in two genes have been shown to cause Lafora disease. The genes encode the proteins laforin and malin, but the molecular mechanism defining how loss of laforin or malin causes Lafora disease has remained unclear.

Jack E. Dixon, Ph.D., UCSD dean of scientific affairs and professor of pharmacology, and colleagues at UCSD investigated the role of malin in Lafora disease and found that malin physically interacts with laforin and regulates laforin’s concentration by marking it for degradation. Their results show that approximately 40 percent of patients with Lafora disease have mutations in malin that render it unable to mark laforin for degradation. This increase in laforin may lead to Lafora disease through aberrant glycogen metabolism.

This work establishes a few testable models as to the molecular mechanism of the disease. Dixon and colleagues are currently designing experiments to test these models with the hope of gaining the necessary insights to develop potential therapies for Lafora disease.

Co-authors are Matthew S. Gentry, Ph.D., and Carolyn A. Worby, Ph.D., both of the UCSD Department of Pharmacy. This research was funded by the National Institutes of Health.

#  #  #

News Media Contact: Leslie Franz or Nancy Stringer, 619-543-6163, healthscicomm@ucsd.edu

Note to broadcast and cable producers: UCSD provides an on-campus satellite uplink facility for live or pre-recorded television interviews.  Please
phone, or e-mail, the media contact listed above to arrange an interview.

UCSD Health Sciences Communications HealthBeat: /news/


Related_Specialties


Media Contact

Share This Article


Related News

1/20/2021
UC San Diego study supports launch of Phase I clinical trial to test a designer DNA agent — an antisense oligonucleotide that targets a gene called IRF4 — in patients with multiple myeloma.
1/12/2021
Researchers at UC San Diego School of Medicine, in collaboration with Dutch scientists, have found that certain metabolites — small molecules produced by the process of metabolism — may be predictive ...
1/10/2021
University of California San Diego Herbert Wertheim School of Public Health and Human Longevity Sciences researchers report that starting tobacco products, including e-cigarettes, before the age of 18 ...
1/7/2021
Chemicals used for vaping break down zipper-like junctions between cells in the gut, leading to chronic inflammation and potential for other health concerns.



Follow Us